AstraZeneca/Sanofi’s RSV treatment shown to reduce hospitalisations in infants

2024-01-09

临床结果上市批准临床研究

AstraZeneca/Sanofi’s RSV treatment shown to reduce hospitalisations in infants

Preview

来源: PMLiVE

AstraZeneca and Sanofi’s Beyfortus (nirsevimab) showed positive results in their HARMONIE trial, demonstrating that the respiratory syncytial virus (RSV) injection could significantly reduce infant hospitalisations.

The trial was co-led by the University Hospital Southampton, the University of Southampton, St George’s University Hospital and the University of Nottingham, with support from the National Institute for Health and Care Research (NIHR).

Responsible for more than 30,000 under-five-year-old hospitalisations every year, RSV is a common respiratory virus that usually causes mild, cold-like symptoms.

However, for some infants, it can cause more severe lung problems, including bronchiolitis and pneumonia.

Involving 8,058 infants under the age of 12 months from the UK, France and Germany, who were either in or approaching their first RSV season, results from the trial showed that a single dose of Beyfortus offered immediate protection against RSV.

Beyfortus, a human monoclonal antibody that is designed to bind to the fusion protein on the surface of the RSV virus, has already received approval from the European Commission and the US Food and Drug Administration to treat newborns and infants during their first RSV season.

Of the 4,037 infants who were randomly assigned to receive the antibody injection, the efficacy of Beyfortus against hospitalisation for RSV-associated lower respiratory tract infection was 89.6% in France, 74.2% in Germany and 83.4% in the UK, with minimal adverse events, in comparison to infants who received no RSV intervention.

Professor Saul Faust, co-study leader and director of NIHR Southampton Clinical Research Facility, said: “These latest results show that this long-acting antibody is safe and could protect thousands of babies from hospitalisation when used in conditions similar to routine clinical practice.”

Dr Simon Royal, NIHR national specialty lead, primary care and honorary assistant professor, University of Nottingham Medical School, said: “This study has shown how primary care clinicians, hospital specialists and the whole UK NIHR system can work together in a new partnership with industry to deliver rapid data to support a critical NHS need.”

Usually occurring from October, peaking in December, until March, the antibody injection could ease the strain that RSV typically causes on NHS resources during the winter season, in both secondary and primary care.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构